Literature DB >> 16266997

Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness.

Xiaolin Zi1, Yi Guo, Anne R Simoneau, Christopher Hope, Jun Xie, Randall F Holcombe, Bang H Hoang.   

Abstract

The ability of Frzb/secreted Frizzled-related protein 3 (sFRP3) to inhibit Wnt signaling and the localization of Frzb/sFRP3 on chromosome 2q to a region frequently deleted in cancers have led some investigators to hypothesize that Frzb/sFRP3 is a tumor suppressor gene. Here, we examined the biological effects of Frzb/sFRP3 on an androgen-independent prostate cancer cell model. We showed that expression of Frzb/sFRP3 in PC-3 cells resulted in decreased colony formation in soft agar and a dramatic inhibition of tumor growth in a xenograft mouse model. When cellular morphology was examined, PC-3 cells expressing Frzb/sFRP3 exhibited an increase in cell-cell contact formation accompanied by a pronounced induction of epithelial markers E-cadherin and keratin-8 and down-regulation of mesenchymal markers N-cadherin, fibronectin, and vimentin. This phenomenon suggested a reversal of epithelial-to-mesenchymal transition and a less invasive phenotype. Indeed, further in vitro studies with a Matrigel assay showed that Frzb/sFRP3 decreased the invasive capacity of PC-3 cells. These changes in the biology of PC-3 cells are associated with a decrease in the expression and activities of both matrix metalloproteinase (MMP)-2 and MMP-9 as well as decreases in AKT activation, cytosolic beta-catenin levels, T-cell factor transcription activity, and expression of Slug and Twist. In addition, transfection of PC-3 with a dominant-negative low-density lipoprotein receptor-related protein 5 (DN-LRP5) coreceptor showed similar biological effects as Frzb/sFRP3 transfection. Together, these data suggest that Frzb/sFRP3 and DN-LRP5 exhibit antitumor activity through the reversal of epithelial-to-mesenchymal transition and inhibition of MMP activities in a subset of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16266997     DOI: 10.1158/0008-5472.CAN-05-0103

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  73 in total

1.  [Expression of secreted frizzled-related protein 4 in DNA mismatch repair-deficient and mismatch repair-proficient colorectal cancers].

Authors:  Kexu Chen; Hanlin Liang; Jiewen Peng; Yanfang Zheng
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-11-30

2.  The activation of beta-catenin by Wnt signaling mediates the effects of histone deacetylase inhibitors.

Authors:  Michael Bordonaro; Darina L Lazarova; Alan C Sartorelli
Journal:  Exp Cell Res       Date:  2007-02-22       Impact factor: 3.905

Review 3.  Matrix metalloproteinase control of capillary morphogenesis.

Authors:  Cyrus M Ghajar; Steven C George; Andrew J Putnam
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2008       Impact factor: 1.807

4.  Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer.

Authors:  Thanh H Dellinger; Kestutis Planutis; Danielle D Jandial; Ramez N Eskander; Micaela E Martinez; Xiaolin Zi; Bradley J Monk; Randall F Holcombe
Journal:  Gynecol Oncol       Date:  2012-04-30       Impact factor: 5.482

5.  WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells.

Authors:  Yaxiong Tang; Anne R Simoneau; Wu-xiang Liao; Guo Yi; Christopher Hope; Feng Liu; Shunqiang Li; Jun Xie; Randall F Holcombe; Frances A Jurnak; Dan Mercola; Bang H Hoang; Xiaolin Zi
Journal:  Mol Cancer Ther       Date:  2009-01-27       Impact factor: 6.261

Review 6.  WNT signalling pathways as therapeutic targets in cancer.

Authors:  Jamie N Anastas; Randall T Moon
Journal:  Nat Rev Cancer       Date:  2013-01       Impact factor: 60.716

7.  Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling.

Authors:  Yi Guo; Jun Xie; Elyssa Rubin; Ya-Xiong Tang; Fritz Lin; Xiaolin Zi; Bang H Hoang
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

8.  Dominant negative LRP5 decreases tumorigenicity and metastasis of osteosarcoma in an animal model.

Authors:  Yi Guo; Elyssa M Rubin; Jun Xie; Xiaolin Zi; Bang H Hoang
Journal:  Clin Orthop Relat Res       Date:  2008-06-20       Impact factor: 4.176

9.  Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients.

Authors:  Martin Schlensog; Lara Magnus; Timon Heide; Julian Eschenbruch; Florian Steib; Maximilian Tator; Vera Kloten; Michael Rose; Erik Noetzel; Nadine T Gaisa; Ruth Knüchel; Edgar Dahl
Journal:  Epigenetics       Date:  2018-04-18       Impact factor: 4.528

Review 10.  Molecular targeted approaches to cancer therapy and prevention using chalcones.

Authors:  Danielle D Jandial; Christopher A Blair; Saiyang Zhang; Lauren S Krill; Yan-Bing Zhang; Xiaolin Zi
Journal:  Curr Cancer Drug Targets       Date:  2014       Impact factor: 3.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.